Clinical efficacy and safety analysis of JAK inhibitors in the treatment of severe acute ulcerative colitis
10.3760/cma.j.cn101480-20240702-00072
- VernacularTitle:JAK抑制剂治疗急性重度溃疡性结肠炎的疗效与安全性分析
- Author:
Fan YIN
1
;
Dongdong HE
;
Xingyu ZHAO
;
Yongquan SHI
;
Kaichun WU
;
Min CHEN
Author Information
1. 空军军医大学第一附属医院消化内科，西安 710032
- Publication Type:Journal Article
- Keywords:
Acute severe ulcerative colitis;
Janus kinase inhibitor;
Upadacitinib;
Tofacitinib;
Efficacy;
Safety
- From:
Chinese Journal of Inflammatory Bowel Diseases
2025;09(3):224-227
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of Janus kinase (JAK) inhibitors in the treatment of acute severe ulcerative colitis (ASUC).Methods:A retrospective cohort study was conducted. Patients with ASUC treated with JAK inhibitors at the First Affiliated Hospital of Air Force Medical University between January 2021 and March 2024 were enrolled. The primary endpoints were clinical response rate at 1 week and colectomy rate at 90 days. The secondary endpoints were clinical response rate and clinical remission rate at 8 weeks, and adverse events rate at 90 days.Results:A total of 15 patients with ASUC (7 men, 8 women; mean age, 42.47±9.92 years) were included. Eight patients were treated with upadacitinib, and 7 with tofacitinib. The clinical response rate at 1 week was 53.3% (8/15), the colectomy rate at 90 days was 20.0% (3/15), the clinical response rate at 8 weeks was 60.0% (9/15), and the clinical remission rate at 8 weeks was 33.3% (5/15). During the 90-day follow-up, only 1 patient (6.7%) treated with tofacitinib experienced a mild leukopenia.Conclusion:JAK inhibitors are effective for ASUC with the high safety.
